In March 2016, two psychologists at the University of Padua published a review article in Frontiers in Human Neuroscience with the deliberately provocative title: "Bread and Other Edible Agents of Mental Disease." It was peer-reviewed, PubMed-indexed, and written, as the authors stated, in deliberately plain English — because they wanted psychiatrists and psychologists to actually read it.
The reception was predictable. Some welcomed it as a necessary challenge to a field that had become over-reliant on pharmacological intervention and under-interested in nutrition. Others dismissed it as scaremongering dressed up in academic language. A prominent science blogger called it "Frontiers' Bread Madness."
Almost nobody engaged seriously with the actual mechanisms — which is a shame, because the mechanisms are where the interesting science is. And a decade on, some of those mechanisms have more supporting evidence than they did in 2016.
Source Paper
Bread and Other Edible Agents of Mental Disease
Bressan P, Kramer P · Front. Hum. Neurosci. 10:130 · March 2016 · PubMed ID: 27065833
A review article examining how cereal grains affect human behaviour and mental health through gut permeability and opioid-like peptide mechanisms. Written by psychologists at the University of Padua to make an interdisciplinary case to colleagues who typically lack training in gastroenterology, immunology, and nutritional science.
Read the full paper → frontiersin.org
Two independent mechanisms — both pointing in the same direction
The paper's core argument is that bread affects mental health through two distinct pathways. These are not alternative theories — they are additive. Both can operate simultaneously. And crucially, both are relevant to people who do not have coeliac disease and do not consider themselves gluten sensitive.
What makes this more than theoretical is the epidemiological data. The paper cites several convergent lines of evidence that are difficult to explain away.
The evidence that should have changed the conversation
World War II — The Natural Experiment
Wheat shortages correlate with falling schizophrenia rates
During WWII, wheat was scarce across multiple European countries. Hospital admissions for schizophrenia dropped significantly during these periods and rose again when wheat consumption returned to pre-war levels. This pattern was observed independently in multiple countries. It’s an ecological observation (populations, not people), so it can’t show cause, and wartime changed far more than wheat.
South Pacific — The Introduction Study
Higher schizophrenia rates reported after grain was introduced
Older reports from South Pacific island populations described schizophrenia becoming more common after Western grain products arrived. These are population observations; I couldn’t find a primary source for the specific figures often quoted, and changes in diagnosis and reporting can’t be ruled out.
Clinical Trials — Gluten-Free Diet in Schizophrenia
Mixed older trials, and a newer signal in one subgroup
Trials from the 1960s to 1980s were mixed: some found patients did better without gluten, and two double-blind challenge studies found no effect. A 2018 systematic review found 9 small studies, 6 of them positive, mostly not randomised (
Levinta 2018). A small double-blind trial in people with schizophrenia and raised anti-gliadin antibodies found better negative symptoms on a gluten-free diet (
Kelly 2019, 16 people). The researchers think this works through the immune system rather than through opioid peptides.
Case Reports — Hallucinations Resolved on Gluten Removal
Daily auditory and visual hallucinations resolved from childhood on GFD
A 2014 case report (Genuis and Lobo) described an adult patient who had experienced highly distressing auditory and visual hallucinations daily from early childhood. Upon removal of gluten from the diet, the hallucinations resolved completely. This was a single case, and one case can’t tell us the mechanism; an immune route fits just as well as an opioid one.
Autism Research — Gluten- and Casein-Free Diets
Small, mixed trials, and the peptides weren’t found
Gluten- and casein-free diets have been tested in small trials in autistic children. Results are mixed: open and single-blind studies look better than double-blind ones, and a 2021 meta-analysis of six randomised trials found no clear effect on core symptoms (
Keller 2021). The mechanism was investigated too: researchers looked for these opioid peptides in children’s urine with more precise methods and didn’t find them (
Cass 2008, 65 autistic boys and 158 controls).
The addiction idea — why some people find gluten hard to give up
One of the paper’s most striking suggestions, and one that will ring true for anyone who has supported a client through a gluten elimination, is an opioid addiction model for food sensitivity.
The reasoning goes: exorphins bind opioid receptors, opioids produce tolerance, and removing an opioid produces withdrawal. The paper suggests that the people most sensitive to gluten are the ones who crave it most. That’s the authors’ argument, not a measured finding: no study has tested opioid-type withdrawal from gluten in people.
"Ironically, the greater the potential benefit of a change in diet, the greater the resistance to it may be. Grain's exorphins can create addiction. It has been estimated that half of the people who are hypersensitive crave the very food that causes them harm and experience withdrawal symptoms when they remove it from their diet."
Many people do find cutting out gluten hard to keep up, and it isn’t a moral failing. Some writers think gluten peptides could drive cravings through opioid receptors, but that has never been tested in people. Habit, convenience and social eating are more certain reasons, and they’re worth planning for.
The zonulin connection — and what a test can and cannot tell you
The gut permeability mechanism described in the Bressan and Kramer paper centres on zonulin — the protein released by intestinal cells in response to gluten that regulates tight junction opening. Alessio Fasano's research group has been documenting the zonulin pathway for over two decades. The pathway is real. Measuring it in a person is the problem.
The GI-MAP stool test — which forms part of the Tier 2 and Tier 3 Resilient Gut System programme — offers zonulin as an add-on, measured in stool. It is not a measure of intestinal permeability. Tested against the sugar-absorption test, stool zonulin tracked permeability only in people who were overweight or obese, in small cohorts (Seethaler 2021). The blood version is worse: commercial kits were found not to detect zonulin at all (Ajamian 2019). A raised stool zonulin is a weak hint, read alongside secretory IgA, calprotectin, symptom history and diet. It is not proof the barrier is open. More in intestinal permeability.
What the paper didn't have in 2016 is still not routinely available: a simple way to measure gut permeability in one person. The reference method, a sugar-absorption test, is used in research rather than in practice. If the gut is more permeable, some exorphins might cross into the blood. If the blood-brain barrier is also weakened, some might reach the brain.
Each step has some lab or animal support, but the chain as a whole has not been measured in one person from start to finish. It is a reasoned hypothesis, not a demonstrated cascade.
The Three-System Overlap: a hypothesis
Some people may sit where three systems meet: gut barrier stress (no routine test measures permeability directly), methylation (MTHFR variant, raised homocysteine, FIGLU on the OAT) and neurotransmitter metabolism (5-HIAA and HVA on the OAT, neurotransmitter metabolites on the DUTCH). The idea that these compound each other, with gut inflammation impairing methylation and impaired methylation lowering neurotransmitters, is plausible but has not been tested as a chain in people. It is a reason to look at all three, not proof that any one of them explains your symptoms or decides whether a treatment will work.
A note on the criticism — and why it matters
The Bressan and Kramer paper has real weaknesses. Several of the studies it cites are small, it extrapolates from rat data to human outcomes, and it was written in plain English for non-specialists, which risks oversimplifying contested science.
These are fair points. The paper is a review, not a clinical trial. It aggregates evidence from multiple disciplines and draws conclusions that the authors acknowledge are hypothesis-generating rather than definitive. The headline claim — that removing bread could cure schizophrenia — is stronger than the underlying evidence base supports as a universal statement.
What matters more is the core mechanism. Gluten-triggered zonulin release is well shown in tissue and cell studies, though not as outcome data in people. Gluten and casein digests contain peptides that bind opioid receptors in the lab; that part is accepted. What’s unproven is whether they reach the brain in amounts that matter, and the best studies that looked for them in children’s urine didn’t find them. No routine test measures them in a person, either.
"The peptides are real. Whether they reach the brain is the open question, and it’s the one the whole argument rests on."
Bringing it back to the flour
This is the third post in a series that started with the UK government's decision to add synthetic folic acid to all non-wholemeal wheat flour from end of 2026. The folic acid story, the MTHFR and mental health story, and this story about gluten, exorphins, and gut permeability are not separate topics. They overlap, though the links between them are weaker than each finding on its own.
Here is what holds up. Folic acid has to be converted by an enzyme (DHFR) that is slow and varies a lot between people in human liver, which fits with unmetabolised folic acid turning up in blood at higher intakes (Bailey & Ayling 2009). Whether that unmetabolised folic acid does any harm has not been shown. Mechanistic
On the other side, fortification is one of the better-evidenced public health measures there is. Across 14 studies covering more than 33 million people, mandatory fortification was linked to 44% fewer neural tube defects (Moges 2026). In the US it raised folate levels and lowered homocysteine in middle-aged and older adults (Jacques 1999). Strong, observational
What has not been studied is whether fortification has any psychiatric effect, good or bad, in the smaller group of people with gut or methylation problems. That is a gap worth naming. It is not a reason to fear bread, or to skip folic acid if you are planning a pregnancy.
Test. Don't guess. Homocysteine, folate status, neurotransmitter metabolites and, if you want it, MTHFR status are all measurable.